In a randomized controlled trial of 118 patients with coronary heart disease and chronic heart failure, the application of YQFM combined with atorvastatin improved cardiac function and delayed ventricular remodeling by decreasing LVEDD, lowering the levels of NT-proBNP, soluble CD40 (sCD40) and soluble CD146 (sCD146), and increasing nitric oxide (NO) levels (Li Y. et al., 2019). This evidence concerns the gene NPPB and congestive heart failure.